Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial.

ABSTRACT:

Background

FGFR genomic aberrations occur in approximately 5-10% of human cancers. Erdafitinib has previously demonstrated efficacy and safety in FGFR-altered advanced solid tumors, such as gliomas, thoracic, gastrointestinal, gynecological, and other rare cancers. However, its efficacy and safety in Asian patients remain largely unknown. We conducted a multicenter, open-label, single-arm phase IIa study of erdafitinib to evaluate its efficacy in Asian patients with FGFR-altered advanced cholangiocarcinoma, non-small cell lung cancer (NSCLC), and esophageal cancer.

Methods

Patients with pathologically/cytologically confirmed, advanced, or refractory tumors who met molecular and study eligibility criteria received oral erdafitinib 8 mg once daily with an option for pharmacody

SUBMITTER: Park JO 

PROVIDER: S-EPMC11323360 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature